Protease inhibitor frequencies: is there a deficit of M subtype heterozygotes?

J B Whitfield1

  • 1Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Human Heredity
|January 1, 1991
PubMed

Insights

Human protease inhibitor (PI) type frequencies vary across populations. Observed PI M subtype homozygote and heterozygote frequencies significantly deviate from Hardy-Weinberg equilibrium predictions, particularly in Europeans.

Area of Science:

  • Population genetics
  • Human genetics
  • Molecular biology

Background:

  • Protease inhibitor (PI) type frequencies are crucial for understanding population genetics.
  • Numerous studies have reported PI type frequencies across diverse human populations.
  • Investigating deviations from expected genetic equilibrium provides insights into evolutionary pressures.

Purpose of the Study:

  • To synthesize and analyze published data on human PI type frequencies.
  • To assess whether observed PI M subtype frequencies align with Hardy-Weinberg equilibrium predictions.
  • To identify population-specific differences in PI M subtype allele distributions.

Main Methods:

  • Meta-analysis of published reports on human PI type frequencies.
  • Statistical comparison of observed genotype frequencies with Hardy-Weinberg equilibrium expectations.
  • Stratification of analysis by major continental populations (Europeans, Asians, Africans).

Main Results:

  • Observed frequencies of PI M subtype homozygotes (M1, M2, M3) were higher than expected under Hardy-Weinberg equilibrium.
  • Observed frequencies of PI M subtype heterozygotes (M1M2, M1M3) were lower than expected.
  • Significant deviations from Hardy-Weinberg equilibrium were most pronounced in European populations.
  • Deviations were less apparent or absent in Asian and African populations.

Conclusions:

  • Human PI M subtype frequencies exhibit significant deviations from Hardy-Weinberg equilibrium in certain populations, notably Europeans.
  • These findings suggest non-equilibrium evolutionary forces may be acting on PI M subtypes in specific human groups.
  • Further research is warranted to elucidate the genetic and environmental factors driving these observed frequency differences.

Related Concept Videos

Mismatch Repair01:48

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.The Mutator Protein Family Plays a Key Role in DNA Mismatch RepairThe human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...